SCHEMBL22556465

SCHEMBL22556465

Nc1nnc(-c2ccccc2Nc2ccc(C(F)(F)F)cc2)o1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 2/20 0.48
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 2/20 0.46
CYP1A2 P05177 1/20 0.46
POLB P06746 1/20 0.46
CYP2C19 P33261 1/20 0.46
HSD17B10 Q99714 1/20 0.46
TAS2R14 Q9NYV8 1/20 0.44
FLT1 P17948 3/20 0.44
KDR P35968 3/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
GFER P55789 1/20 0.43
ABCG2 Q9UNQ0 1/20 0.43
NOTUM Q6P988 2/20 0.43
RAB9A P51151 1/20 0.40
CTDSP1 Q9GZU7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9263048 0.87 MAPT (0.58) ALDH1A1TAS2R14FLT1KDRGAA
SCHEMBL22571428 0.85 GSK3B (0.47) GSK3BKDM4EALDH1A1CYP1A2POLB
SCHEMBL22556470 0.85 GSK3B (0.47) GSK3BKDM4EALDH1A1CYP1A2POLB
SCHEMBL22571365 0.85 KDM4E (0.51) GSK3BKDM4EALDH1A1CYP1A2POLB
SCHEMBL30463770 0.85 GSK3B (0.44) GSK3BKDM4EALDH1A1CYP1A2POLB
SCHEMBL22556503 0.85 GSK3B (0.44) GSK3BKDM4EALDH1A1CYP1A2POLB
SCHEMBL22556467 0.83 GSK3B (0.54) GSK3BKDM4EALDH1A1CYP1A2POLB
SCHEMBL22571368 0.83 GSK3B (0.45) GSK3BKDM4EALDH1A1CYP1A2POLB
SCHEMBL22556564 0.83 GSK3B (0.45) GSK3BKDM4EALDH1A1CYP1A2POLB
SCHEMBL22571341 0.83 GSK3B (0.43) GSK3BKDM4EALDH1A1CYP1A2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116761795-A Inhibitors of Transcription Enhancement Associated Domain (TEAD) and uses thereof 达纳-法伯癌症研究所股份有限公司 2023-09-15 CN disclosed
US-11661403-B2 Oxadiazole compounds VIVACE THERAPEUTICS, INC. (US) 2023-05-30 US disclosed
US-11661403-B2 Oxadiazole compounds VIVACE THERAPEUTICS, INC. (US) 2023-05-30 US disclosed
US-11661403-B2 Oxadiazole compounds VIVACE THERAPEUTICS, INC. (US) 2023-05-30 US disclosed
US-20210238154-A1 OXADIAZOLE COMPOUNDS VIVACE THERAPEUTICS, INC. 2021-08-05 US disclosed
US-20210238154-A1 OXADIAZOLE COMPOUNDS VIVACE THERAPEUTICS, INC. 2021-08-05 US disclosed
EP-3793551-A1 OXADIAZOLE COMPOUNDS Vivace Therapeutics, Inc. (US) 2021-03-24 EP disclosed
WO-2019222431-A9 OXADIAZOLE COMPOUNDS VIVACE THERAPEUTICS, INC. (US) 2020-10-22 WO disclosed
WO-2019222431-A9 OXADIAZOLE COMPOUNDS VIVACE THERAPEUTICS, INC. (US) 2020-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238154-A1 OXADIAZOLE COMPOUNDS YAP1, TEAD2, TEAD3 GSK3B 193/4885KDM4E 1591/4885ALDH1A1 2353/4885
US-11661403-B2 Oxadiazole compounds YAP1, TEAD2, TEAD3 GSK3B 193/4885KDM4E 1591/4885ALDH1A1 2353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.